Although many types of neurons are damaged or destroyed in Alzheimer's disease, few seem to fare so badly as the cholinergic cells which arise in the basal forebrain, terminate in the hippocampal and cerebral cortex, and enable some memory functions (compare with reference 1). Identifying the biochemical processes which underlie the selective vulnerability of these cells has been a continuing focus of Alzheimer's disease research. A potential candidate is the propensity of these cells to use choline for two purposes: to phosphorylate it, ultimately generating a major membrane phospholipid, phosphatidylcholine (PC), a pathway they share with all other cells; and to acetylate it to form the neurotransmitter acetylcholine (ACh). Both of the neuronal enzymes which act on choline, choline kinase and choline acetyltransferase, have unusually low affinities for this substrate and are thus unsaturated at normal brain choline levels. Thus, they rapidly synthesize more product when substrate levels increase (e.g., after administration of compounds that raise plasma choline levels [1] ). However, when cholinergic neurons are physiologically active, they selectively shunt available free choline to the ACh pathway, increasing the turnover of membrane PC and slowing its synthesis, and, if unchecked by giving supplemental choline, actually decrease the amounts of membrane phospholipids per cell (1) . This process, a kind of "autocannibalism" is perhaps analogous to the bone demineralization which occurs with prolonged vitamin D deficiency.
The discovery that providing choline could promote ACh release in model systems (1) 
